175 related articles for article (PubMed ID: 8008980)
21. [Treatment of chronic viral hepatitis B in children with moderate doses of alpha interferon].
Cullu F; Tümay GT; Kutlu T; Erkan T; Ozbay G; Badur S
Gastroenterol Clin Biol; 1995 Jan; 19(1):53-7. PubMed ID: 7720991
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic hepatitis B with beta interferon given intramuscularly: a pilot study.
Capalbo M; Actis C; Maurizia R; Brunetto R; Poli G; Baldi M; Palmisano L; Verme G; Bonino F
Ital J Gastroenterol; 1992 May; 24(4):203-5. PubMed ID: 1600196
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of serum and urinary neopterin levels in patients with various liver diseases.
Daito K; Suou T; Kawasaki H
Am J Gastroenterol; 1992 Apr; 87(4):471-6. PubMed ID: 1313206
[TBL] [Abstract][Full Text] [Related]
24. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of chronic hepatitis B with interferon alpha-2b].
Baumgarten R; Müller R; Markus R; Hintsche-Kilger B; Fengler JD; Meisel H
Gastroenterol J; 1990; 50(3):124-8. PubMed ID: 2288653
[TBL] [Abstract][Full Text] [Related]
26. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.
Barbera C; Bortolotti F; Crivellaro C; Coscia A; Zancan L; Cadrobbi P; Nebbia G; Pillan MN; Lepore L; Parrella T
Hepatology; 1994 Aug; 20(2):287-90. PubMed ID: 8045488
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
28. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.
Wong DK; Yim C; Naylor CD; Chen E; Sherman M; Vas S; Wanless IR; Read S; Li H; Heathcote EJ
Gastroenterology; 1995 Jan; 108(1):165-71. PubMed ID: 7806038
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of interferon alpha-2b following prednisone withdrawal in the treatment of chronic viral hepatitis B. A case-controlled, randomised study.
Robson SC; Brice E; van Rensburg C; Kannemeyer J; Hift RJ; Kirsch RE
S Afr Med J; 1992 Nov; 82(5):317-20. PubMed ID: 1448711
[TBL] [Abstract][Full Text] [Related]
30. Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally.
Zielińska W; Paszkiewicz J; Korczak A; Własiuk M; Zółtowska A; Szutowicz A; Cummins JM; Georgiades JA
Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):241-51. PubMed ID: 8129568
[TBL] [Abstract][Full Text] [Related]
31. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
32. [The treatment of patients with chronic persistent hepatitis B with interferon preparations].
Kokoreva LN; Zmyzgova AV; Shalygina NB
Ter Arkh; 1995; 67(6):43-5. PubMed ID: 7667778
[TBL] [Abstract][Full Text] [Related]
33. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
34. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
35. Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M
Gastroenterol Jpn; 1990 Feb; 25(1):70-7. PubMed ID: 2106467
[TBL] [Abstract][Full Text] [Related]
36. [2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells obtained from patients with chronic hepatitis B during interferon therapy].
Sugawara T
Hokkaido Igaku Zasshi; 1990 Sep; 65(5):439-54. PubMed ID: 2227795
[TBL] [Abstract][Full Text] [Related]
37. [Activation of the interferon system enzymes by recombinant alpha2-interferon in patients with chronic hepatitis B].
Sokolova TM; Bugaeva NP; Suetina IA; Ershov FI; Ketiladze ES
Antibiot Khimioter; 1989 Jun; 34(6):472-5. PubMed ID: 2552947
[TBL] [Abstract][Full Text] [Related]
38. Elevation of 2',5'-oligoadenylate synthetase activity and HLA-I associated beta 2-microglobulin in response to recombinant interferon-gamma administration in chronic HBeAg-positive hepatitis.
Quiroga JA; Mora I; Porres JC; Carreño V
J Interferon Res; 1988 Dec; 8(6):755-63. PubMed ID: 3148006
[TBL] [Abstract][Full Text] [Related]
39. [Effect of interferon on hepatitis B virus infection in patients with chronic active hepatitis].
Hinoue Y; Unoura M; Kato Y; Kobayashi K; Hattori N
Gan To Kagaku Ryoho; 1984 Feb; 11(2):205-11. PubMed ID: 6696458
[TBL] [Abstract][Full Text] [Related]
40. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease.
Davidsen B; Munkholm P; Schlichting P; Nielsen OH; Krarup H; Bonnevie-Nielsen V
Aliment Pharmacol Ther; 1995 Feb; 9(1):75-9. PubMed ID: 7766748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
